Bob Motzer, MD, joins the discussion on IPI/Nivo versus VEGF/PD1 to give his perspective on the recent debate from ASCO 2023.
Dr. Motzer is Section Head, Kidney Cancer, Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center, and is the Jack and Dorothy Byrne Chair in Clinical Oncology.